AU2022316959A1 - Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome - Google Patents

Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome Download PDF

Info

Publication number
AU2022316959A1
AU2022316959A1 AU2022316959A AU2022316959A AU2022316959A1 AU 2022316959 A1 AU2022316959 A1 AU 2022316959A1 AU 2022316959 A AU2022316959 A AU 2022316959A AU 2022316959 A AU2022316959 A AU 2022316959A AU 2022316959 A1 AU2022316959 A1 AU 2022316959A1
Authority
AU
Australia
Prior art keywords
patient
administration
change
stem cells
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022316959A
Other languages
English (en)
Inventor
Joshua M. Hare
Sunjay Kaushal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of AU2022316959A1 publication Critical patent/AU2022316959A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022316959A 2021-07-26 2022-07-26 Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome Pending AU2022316959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203519P 2021-07-26 2021-07-26
US63/203,519 2021-07-26
PCT/US2022/038370 WO2023009537A1 (en) 2021-07-26 2022-07-26 Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome

Publications (1)

Publication Number Publication Date
AU2022316959A1 true AU2022316959A1 (en) 2024-02-29

Family

ID=83049982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022316959A Pending AU2022316959A1 (en) 2021-07-26 2022-07-26 Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome

Country Status (9)

Country Link
US (1) US20240350549A1 (https=)
EP (1) EP4376950A1 (https=)
JP (1) JP2024527034A (https=)
KR (1) KR20240040776A (https=)
CN (1) CN117999082A (https=)
AU (1) AU2022316959A1 (https=)
CA (1) CA3227475A1 (https=)
TW (1) TW202321437A (https=)
WO (1) WO2023009537A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025062365A1 (en) * 2023-09-22 2025-03-27 Mesoblast International Sárl Mesenchymal lineage precursor or stem cells (mlpscs) for use in methods of treating congenital heart disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180105705A (ko) 2016-02-04 2018-09-28 롱에버론 엘엘씨 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법
JP7276664B2 (ja) 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
SG11201912209UA (en) 2017-06-19 2020-01-30 Longeveron Llc Treatment of sexual dysfunction and improvement in sexual quality of life
AU2020356193A1 (en) * 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions

Also Published As

Publication number Publication date
TW202321437A (zh) 2023-06-01
KR20240040776A (ko) 2024-03-28
CN117999082A (zh) 2024-05-07
WO2023009537A1 (en) 2023-02-02
EP4376950A1 (en) 2024-06-05
CA3227475A1 (en) 2023-02-02
JP2024527034A (ja) 2024-07-19
US20240350549A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
Rupp et al. Intracoronary bone marrow cell application for terminal heart failure in children
Tuma et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina
Tarui et al. Stem cell therapies in patients with single ventricle physiology
Povsic et al. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations
US20240350549A1 (en) Use of Mesenchymal Stem Cells in Treatment of Juvenile Hypoplastic Left Heart Syndrome
CN104862281A (zh) 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途
Weale et al. Adult congenital heart disease
Haller et al. Surgical strategies in single ventricle management of neonates and infants
Qureshi et al. Cell-based therapy for myocardial dysfunction after fontan operation in hypoplastic left heart syndrome
US20190224240A1 (en) Cell therapy for the treatment of non-ischemic heart failure
Wehman et al. Stem cell therapy for CHD: towards translation
HK40103434A (zh) 间充质干细胞在治疗青少年左心发育不良综合征中的用途
Tabbah et al. Surviving a single ventricle and a single atrium with a situs inversus viscerum
CN113425731B (zh) 一种增效干细胞治疗心梗的药物及其应用
Ristić-Andjelkov et al. Left ventricular noncompaction in a patient presenting with a left ventricular failure
Juan et al. Two cases of anomalous origin of left coronary artery from the pulmonary artery
Weale et al. Adult congenital heart disease
Qiu et al. Congenital atresia of the left main coronary artery with left ventricular noncompaction: From infancy to adulthood
Lācis MEDICINE & NUTRACEUTICAL RESEARCH
Shah et al. EARLY OUTCOMES OF TOTAL CORRECTION IN TETRALOGY OF FALLOT IN A TERTIARY CARE HOSPITAL OF PESHAWAR, KHYBER PAKHTUNKHWA, PAKISTAN; A TWO-YEAR RETROSPECTIVE STUDY.
Selvan et al. Long-term follow-up of persistent truncus arteriosus: Kuwait experience
Ristić-AnĎelkov et al. PRESENTING WITH A LEFT VENTRICULAR FAIILURE NEKOMPAKTNA LEVA KOMORA KAO UZROK SRČANE SLABOSTI
Gery et al. Comparing outcomes of active closure versus natural evolution in hemodynamically significant restrictive PmVSDs: Insights from the FRANCISCO cohort
Lacy-Niebla et al. Surgical treatment of intracardiac teratoma in a 66 years-old man. Case report
DURAISAMY BALAGURU TRUNCUS ARTERIOSUS